Callisto Pharmaceuticals Inc - Current report filing (8-K)
09 July 2008 - 6:46AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported):
July 1, 2008
Callisto
Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-32325
|
|
13-3894575
|
(State or other jurisdiction
|
|
(Commission
|
|
IRS Employer
|
of incorporation or organization)
|
|
File Number)
|
|
Identification No.)
|
420 Lexington Avenue, Suite 1609
New York, New York 10170
(Address of principal executive offices)
Registrants telephone number, including area code:
(212) 297-0010
(Former name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
o
Written communication pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Item 3.01.
Notice of Delisting or
Failure to Satisfy a Continued Listing Rule or Standard; Transfer of
Listing.
As
previously reported in the Current Report on Form 8-K of Callisto
Pharmaceuticals, Inc. (the Company) dated as of April 11, 2008, the
Company received notice from the staff of the American Stock Exchange (AMEX)
indicating that it intends to strike the Companys common stock from listing on
AMEX by filing a delisting application with the Securities and Exchange
Commission. In its letter, AMEX stated that it has determined that the Company
has failed to comply with continued listing standards set forth in Sections
1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the AMEX Company Guide,
respectively, which state, in relevant part, that AMEX will normally consider
suspending dealings in, or removing from the list, securities of a company
which (a) has stockholders equity of less than $2,000,000 if such company
has sustained losses from continuing operations and/or net losses in two of its
three most recent fiscal years; (b) has stockholders equity of less than
$4,000,000 if such company has sustained losses from continuing operations
and/or net losses in three of its four most recent fiscal years; or (c) has
stockholders equity of less than $6,000,000 if such company has sustained
losses from continuing operations and/or net losses in its five most recent
fiscal years, respectively.
The
AMEX rules provide for an appeal of the above decision and the Company
requested a hearing in accordance with appropriate procedures as outlined by
the Company Guide. The hearing was held
on June 25, 2008.
On
July 1, 2008, the Company received notice from the AMEX indicating that
the AMEX will initiate the delisting process with respect to the Companys
common stock, in accordance with Part 12 of the Company Guide. The Company
is taking the necessary steps to have its common stock traded on the
Over-the-Counter Bulletin Board.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
2
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: July 8,
2008
|
CALLISTO
PHARMACEUTICALS, INC.
|
|
|
|
|
|
By:
|
/s/
Gary S. Jacob
|
|
|
Gary S. Jacob, Ph.D.
|
|
Chief Executive Officer
|
3
Callisto (AMEX:KAL)
Historical Stock Chart
From Nov 2024 to Dec 2024
Callisto (AMEX:KAL)
Historical Stock Chart
From Dec 2023 to Dec 2024